Qiagen (NYSE:QGEN) Shares Gap Up - What's Next?

Qiagen (NYSE:QGEN - Get Free Report)'s stock price gapped up before the market opened on Thursday . The stock had previously closed at $40.02, but opened at $41.44. Qiagen shares last traded at $40.31, with a volume of 389,458 shares.

Analyst Upgrades and Downgrades

QGEN has been the topic of several research analyst reports. Baird R W cut Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Robert W. Baird downgraded shares of Qiagen from an "outperform" rating to a "neutral" rating and cut their price target for the company from $52.00 to $42.00 in a report on Wednesday, February 19th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $46.67 price objective (down previously from $48.61) on shares of Qiagen in a research note on Monday, January 6th. Redburn Atlantic cut Qiagen from a "buy" rating to a "neutral" rating in a report on Friday. Finally, UBS Group decreased their target price on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Eight research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $47.71.

Qiagen Stock Down 2.1 %

The business has a fifty day moving average price of $40.20 and a two-hundred day moving average price of $41.91. The company has a current ratio of 3.61, a quick ratio of 3.09 and a debt-to-equity ratio of 0.38. The company has a market cap of $8.77 billion, a price-to-earnings ratio of 109.65, a P/E/G ratio of 2.39 and a beta of 0.62.

Remove Ads

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The company reported $0.61 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.01. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. On average, equities analysts predict that Qiagen will post 2.26 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of QGEN. Brown Brothers Harriman & Co. bought a new stake in shares of Qiagen in the fourth quarter valued at approximately $37,000. Geneos Wealth Management Inc. boosted its holdings in Qiagen by 41.5% in the 4th quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock valued at $38,000 after purchasing an additional 251 shares during the period. EverSource Wealth Advisors LLC grew its position in Qiagen by 152.5% in the 4th quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares during the last quarter. Wilmington Savings Fund Society FSB bought a new position in shares of Qiagen during the 3rd quarter worth about $53,000. Finally, Smartleaf Asset Management LLC raised its position in shares of Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock valued at $63,000 after buying an additional 835 shares during the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.